Reagent disc structure for drug sensitivity test

Abstract

The utility model relates to a reagent disc structure for a drug sensitivity test. The reagent disc structure structurally comprises a test carrier, at least two supporting and limiting parts, a central injection part, a plurality of micro-channels, a plurality of reaction tanks, a plurality of preset reagents special for AST, a plurality of overflow channels, a plurality of overflow tanks, a plurality of reducing parts and a plurality of exhaust holes. Before the test carrier is packaged, a freeze-dried preset reagent is placed in the reaction tank in advance, after a user adds a specimen from the central injection part, the test carrier can be directly arranged in the test device, the specimen uniformly flows into the reaction tank from the micro-channel under the action of centrifugal force when the test device is started, and if the content of the specimen in the reaction tank is greater than the volume of the specimen, the test carrier can be directly placed in the test device. And the gas generated in the reaction can be discharged from the exhaust hole, so that the gas can flow into the overflow groove along the tapered part of the overflow groove channel. Therefore, the pre-test steps can be simplified, the specimens can be uniformly distributed in a proper amount, the cross infection of the specimens is avoided, and the pollution caused by the carrier collapsed by excessive gas is avoided.

Description

[Technical Field]

[0001] This invention provides a reagent disc structure for drug sensitivity testing that simplifies the pre-test steps, allows for simultaneous testing of multiple drug susceptibility tests, provides uniform and appropriate sample distribution, and offers space and venting holes for independent sample reaction. It is characterized by simple operation, uniform concentration, sufficient bacterial count, and avoids cross-infection of samples and reduces the likelihood of uninterpretable results due to human error. [Background Technology]

[0002] Antimicrobial susceptibility testing (AST), also known as antimicrobial agent susceptibility testing, is a test designed to assess the susceptibility of bacteria, fungi, or other microorganisms to antimicrobial agents (such as antibiotics) in order to select the most effective treatment.

[0003] The traditional AST process involves first culturing bacteria, diluting them to a usable concentration, preparing a petri dish, dropping the diluted bacterial solution into the petri dish for spreading, then adding antibiotic paper strips of known concentration to the petri dish, allowing it to grow and react at an appropriate temperature for a period of time, and finally measuring the size of the inhibition zone to visually record and determine whether the antibiotic is an effective treatment for the bacterial species.

[0004] Currently, there is an AST testing device and its disc on the market that claims to be able to complete the test quickly. The operation steps are as follows: first, collect the sample and dilute it, then add the indicator to the bacterial solution and mix them together, then inject them into the disc, and finally put it into the device for reaction. After the reaction is completed, the color of the reagent is used to judge the result.

[0005] The above-mentioned AST testing equipment and its disks have the following problems and deficiencies that need to be improved during use:

[0006] First, although this step is faster than the traditional process, it is also prone to problems with individual operating techniques, resulting in uneven indicator concentration and staining, which leads to problems in the interpretation of results. In addition, there are still four or five steps for the operator, and the more steps there are, the easier it is to cause contamination or infection.

[0007] Secondly, the volume of each reaction tank on the disc is less than 20 μl, which means that the pathogenic bacteria cannot grow normally during the reaction due to the small amount of bacteria. On the other hand, the strong competition from antibiotics also prevents the bacteria from growing normally, making it impossible to interpret the test results of this disc.

[0008] Third, each reaction cell on the disc is interconnected, which can easily cause cross-infection. Because the bacteria naturally spread from the first reaction cell to the last reaction cell, it can easily cause uneven bacterial concentration and large differences in bacterial count. Furthermore, the indicators and samples in each reaction cell can affect each other, which can lead to the inability to interpret the results.

[0009] Fourth, the disc is not designed with venting holes because bacteria will produce gas during the reaction process. Since the space inside the disc is closed, if the gas is not released in time, the more bacteria there are, the more gas there will be, which will easily squeeze the membrane on the top of the disc and cause the disc to break open, resulting in leakage and contamination.

[0010] How to solve the aforementioned problems and shortcomings of conventional methods is the direction that the applicant of this utility model and related manufacturers in this industry urgently want to study and improve. [Utility Model Content]

[0011] The main purpose of this invention is to utilize the independent radially spaced arrangement of microchannels, allowing the sample to be added through a single central injection point and placed into a testing device for reaction testing, thus greatly simplifying the operation steps and enabling uniform distribution of the sample volume.

[0012] Another major objective of this invention is to: configure equal amounts of pre-prepared reagents in each reaction tank ranging from 20 μl to 80 μl, eliminating the need for manual reagent addition, ensuring that the amount and concentration of reagents in each reaction tank are equivalent, and that the amount of bacterial solution in each reaction tank is consistent, thereby ensuring high integrity and accuracy of AST experimental results.

[0013] Another major objective of this invention is to utilize the design of the overflow channel and overflow trough so that when the sample volume is greater than the reaction tank volume, it flows to the overflow trough, thereby effectively controlling the bacterial count, improving experimental accuracy, and avoiding bacterial backflow that could lead to cross-infection.

[0014] Another major objective of this invention is to allow gas to escape during the reaction process by utilizing the design of the vent hole, thereby preventing the test carrier from being damaged by excessive gas and indirectly avoiding infection caused by leakage.

[0015] To achieve the above objectives, the structure of this utility model includes: a test carrier, at least two supporting and limiting portions, a central injection portion for adding a sample, a plurality of radially arranged and independent microchannels, a plurality of reaction tanks, a plurality of pre-prepared reagents for AST, a plurality of overflow channels, a plurality of overflow troughs, a plurality of tapered portions, and a plurality of vent holes. The central injection portion is disposed on the test carrier, the supporting and limiting portions are formed within the test carrier, the microchannels are radially arranged at intervals on the side of the central injection portion and are each connected to it, the reaction tanks are respectively disposed on each microchannel, the pre-prepared reagents are placed in each reaction tank, the overflow channels are respectively formed on the side of each reaction tank opposite to each microchannel and are connected to it, the overflow troughs are respectively formed on one side of each overflow channel and are connected to it, the tapered portions are formed on each overflow channel, and the vent holes are respectively disposed on one side of each overflow trough and are connected to it.

[0016] When users use this invention to conduct drug sensitivity testing, since the reaction tank of the test carrier has been pre-filled with freeze-dried pre-prepared reagents before packaging, users only need to add the sample through the central injection section to set the test carrier in a test device to prepare for start-up. During injection, the support limiting part restricts the insertion depth of the injection tool, which can avoid damaging the sealing film and ensure complete injection of the sample. The pre-treatment steps are very simple and basically eliminate the problem of human operation. When the test carrier rotates, the sample, due to centrifugal force, flows from several radially spaced microchannels into reaction tanks with volumes ranging from 20 μl to 80 μl. After all the sample flows out of the central injection section, the portion of the sample content in each reaction tank that exceeds its volume flows into the corresponding overflow tank through overflow channels. Due to the tapered design, the maximum flow rate into the overflow tank can be reduced. Then, the sample reacts with the pre-placed reagents in each reaction tank. The gas generated during the reaction is discharged from the test carrier through the vent. In this way, the sample can be evenly distributed into each microchannel, and the sample volume in each reaction tank can be stably controlled. In addition, the pre-placed freeze-dried reagents in the reaction tank make all conditions easy to control, improving the integrity and accuracy of the experiment. Furthermore, the design of independent channels and vents can avoid the risk of cross-contamination.

[0017] The above technologies can overcome the problems of cumbersome pre-testing steps, human operation, uneven bacterial concentration, insufficient bacterial quantity, inability to remove excess gas, insufficient test accuracy, and easy cross-contamination in AST testing equipment and its disks. [Attached Image Description]

[0018] Figure 1 This is a perspective view of the first preferred embodiment of the present invention.

[0019] Figure 2This is a schematic diagram of the reagent pre-positioning in the first preferred embodiment of the present invention.

[0020] Figure 3 This is a schematic diagram of the sample injection in the first preferred embodiment of the present invention.

[0021] Figure 4 This is a schematic diagram of the sample diversion in the first preferred embodiment of the present invention.

[0022] Figure 5 This is a schematic diagram of the sample overflow in the first preferred embodiment of the present invention.

[0023] Figure 6 This is a schematic diagram of the reaction in the first preferred embodiment of the present invention.

[0024] Figure 7 This is an exploded view of the second preferred embodiment of the present invention.

[0025] Figure 8 This is an exploded view of the third preferred embodiment of the present invention.

[0026] Figure 9 This is a perspective sectional view of the fourth preferred embodiment of the present invention.

[0027] Figure 10 This is a perspective view of the fifth preferred embodiment of the present invention.

[0028] Figure 11 This is a perspective sectional view of the fifth preferred embodiment of the present invention.

[0029] Figure 12 This is a plan view of the sixth preferred embodiment of the present invention.

[0030] [Symbol Explanation]

[0031] Test carrier...1

[0032] Lower disc...11

[0033] Positioning Department...111

[0034] Support limit part...112

[0035] Upper disc...12

[0036] Fixing part...13

[0037] Error prevention department...14

[0038] Central injection section...2

[0039] Specimen storage area...21

[0040] Inlet...22

[0041] Flow limiting slot...23

[0042] Microchannels...3

[0043] Reaction tank...4

[0044] Pre-prepared reagents...41

[0045] Convergence slot...42

[0046] Overflow channel...5

[0047] taper section...51

[0048] Overflow channel...6

[0049] Exhaust port...7

[0050] Test equipment...8

[0051] Axis...81

[0052] Fasteners...82

[0053] Mistake-proof indicator...83

Detailed Implementation Methods

[0054] To achieve the above objectives and effects, the technical means and structure adopted by this utility model are described in detail below with reference to the preferred embodiment of this utility model.

[0055] Please see Figures 1 to 6 The figure shown is a perspective view of the first preferred embodiment of the present invention, which can be clearly seen from the figure as including:

[0056] Test carrier 1;

[0057] At least two support limiting parts 112 are formed inside the test carrier 1 to support the test carrier 1;

[0058] A central injection unit 2 is provided between each of the support limiting units 112 for adding the sample.

[0059] The insertion depth of an injection tool is limited by each of the support limiting parts 112;

[0060] Several microchannels 3 are arranged radially at intervals on the side of the central injection section 2 and are connected to each other, so that when the test carrier 1 rotates, the sample flows into each microchannel 3 evenly by centrifugal force.

[0061] Several reaction tanks 4 are respectively disposed on each of the microchannels 3, and the volume of each reaction tank 4 is 20μl to 80μl;

[0062] If the intervention reagent 41 is placed in each of the reaction tanks 4, and each of the pre-placed reagents 41 is a reagent specifically for drug sensitivity testing;

[0063] Several overflow channels 5 are formed on the side of each reaction tank 4 away from each microchannel 3 and are connected to it;

[0064] Several overflow channels 6 are formed on one side of each overflow channel 5 and are connected to it;

[0065] A plurality of tapered portions 51 are formed on each of the overflow channels 5, and the openings connecting one side of each of the reaction tanks 4 are larger than the openings connecting one side of each of the overflow channels 6; and

[0066] Several vent holes 7 are respectively located on one side of the overflow channel 6 and connected to it.

[0067] The test carrier 1 is a transparent circular disk, and its material is not limited; for example, it can be PC (…).

[0068] Taking a transparent polycarbonate disc composed of an upper disc 12 and a lower disc 11 as an example, the upper disc 12 and the lower disc 11 are supported by multiple supporting and limiting parts 112. In this embodiment, two are used as an example. The bottom center of the lower disc 11 has a positioning part 111 for pivoting the testing device 8. The positioning part 111 is a groove with a downward opening. The central area between the upper disc 12 and the lower disc 11 forms the central injection part 2. The central injection part 2 includes a sample placement area 21 between the upper disc 12 and the lower disc 11, and an injection port 22 formed in the center of the upper disc 12 and communicating with the sample placement area 21. The injection port 22 is formed between the supporting and limiting parts 112 to limit the insertion depth of the injection tool. In this embodiment, the injection tool is a dropper as an example. The microchannels 3 are arranged in 36 equidistant intervals, so the reaction tank 4, overflow channel 5, and overflow channel 6 are also included. The quantity is 36 in each case, and in this embodiment, each case is formed by integrally extending upward from the upper surface of the lower plate 11. The vent holes 7 are 36 channels connecting each overflow groove 6 and the surface of the upper plate 12. The pre-prepared reagent 41 is a combination of color indicator, excipient, antifreeze, and antibiotic. In this embodiment, the indicator is resazurin or 2,3,5-triphenyltetrazolium chloride, which are specifically used for AST. The excipient is used to shape and fix the pre-prepared reagent 41 in the reaction tank 4 to avoid the pre-prepared reagent 41 from being scattered to other places or adhering to the wall due to the powder structure, resulting in inconsistent concentrations in each reaction tank 4. The antifreeze is used in the freeze-drying process of the pre-prepared reagent 41 to keep the pre-prepared reagent 41 at a low temperature and dry without freezing. The antibiotic is the target of the AST experiment. The tapered parts 51 are stepped or sloping. In this embodiment, the stepped shape is used as an example. However, the corresponding forms of the above-mentioned components are merely examples of preferred embodiments. Any form with the same function falls within the scope of this utility model and is not limited to the examples above.

[0069] The above explanation has provided an understanding of the structure of this technology. Based on the corresponding configuration of this structure, the pre-test steps can be simplified, multiple drug sensitivity tests can be performed simultaneously, the sample can be evenly and appropriately distributed, and independent reaction space and vent 7 can be provided for the sample. This achieves advantages such as simple operation, uniform concentration, sufficient bacterial count, avoidance of cross-infection of samples, and reduction of results that cannot be interpreted due to human error. As can be clearly seen in the figure, the reaction tank 4 contains pre-placed reagents 41. Because these reagents are pre-placed before the test carrier 1 is packaged, the dosage and concentration do not need to be controlled by the user. Furthermore, the pre-placed reagents 41 are freeze-dried, resulting in higher consistency in dosage and concentration, and high stability in preserving antibiotics, which is beneficial for extending storage time and facilitating transportation. Therefore, when performing AST experiments, the pre-placed reagents 41 are more suitable for the test carrier 1. For the user, the only steps are adding the sample to the central injection section 2 and placing the test carrier 1 in a test device 8 to prepare for activation. The preliminary steps are very simple, basically eliminating the problem of human operation. Since the action of adding the sample is generally done with a dropper, and the test carrier 1 of this case has a ring-shaped arrangement of support and limiting parts 112, the space surrounded by which is the injection port 22, the user only needs to hold the dropper against the injection port 22 during operation. The support and limiting parts 112 can be used to reduce the diameter of the central injection section 2. In this way, the dropper will be against the support and limiting parts 112 and will not touch the bottom sealing film. By limiting the insertion depth of the injection tool, it can prevent the bottom sealing film from falling off or being damaged due to excessive insertion, and also ensure that the sample is completely injected into the test carrier 1, thereby reducing side leakage and improving the accuracy of the sample volume.

[0070] When the test carrier 1 rotates, the sample flows into each reaction tank 4 through several radially spaced microchannels 3 due to centrifugal force. This design makes each microchannel 3 an independent channel, and the sample flowing into any microchannel 3 will not come into contact with the sample in other microchannels 3. Also, because the sample is not delivered by natural diffusion, but by centrifugal force, the sample in the central injection section 2 can be evenly dispersed into each microchannel 3, resulting in a balanced dose.

[0071] Next, the sample flows through each microchannel 3 to the reaction tank 4 in the same path. Since the volume of the reaction tank 4 is 20μl to 80μl, it is relatively sufficient compared to the conventional bacterial load. If the bacterial load is too small, it is easily overcompeted by antibiotics, making the results uninterpretable. However, if the bacterial load is too large, the antibiotics are easily overcompeted by bacteria, making the test results unreliable. Therefore, this design uses a volume of 20μl to 80μl for the reaction tank 4 to provide the most appropriate bacterial load, which is conducive to conducting complete and accurate AST experiments. This embodiment uses the optimal volume of 50μl for the reaction tank 4 as an example. Of course, after all the sample flows out of the central injection section 2, the portion of the sample content in each reaction tank 4 that is greater than its volume is simply isolated by flowing into the overflow tank 6 through the overflow channel 5. Therefore, this design allows for a small amount of bacterial solution to overflow from the reaction tank 4, which can stably control the sample volume in each reaction tank 4. With the addition of the freeze-dried pre-prepared reagent 41, all conditions are easy to control, thereby improving the integrity and accuracy of the experiment.

[0072] Furthermore, in this embodiment, the extension direction of each microchannel 3 and each overflow channel 5 is towards the central injection section 2. In the same reaction tank 4, the overflow channel 5 is located on the side of the microchannel 3 away from the rotation direction of the test carrier 1. In other words, due to centrifugal force, the bacterial solution in the reaction tank 4 will concentrate towards the side of the reaction tank 4 away from the central injection section 2. The opening of the overflow channel 5 connecting to the reaction tank 4 is designed on the side of the reaction tank 4 close to the central injection section 2. Therefore, under normal circumstances, the bacterial solution will not enter the overflow channel 5. If the rotation direction of the test carrier 1 is clockwise, the overflow channel 5 will be set on the counterclockwise side of the microchannel 3. In this way, even if there is bacterial solution in the overflow channel 6, it is difficult to return to the reaction tank 4 through the overflow channel 5 during the rotation process, so as to avoid backflow. In particular, this invention features a tapered section 51 on the overflow channel 5. The opening of the tapered section 51 on the side connecting each of the reaction tanks 4 is larger than the opening on the side connecting each of the overflow channels 6. This means that by using the tapered inlet size, the maximum flow rate into the overflow channel 6 is reduced. Alternatively, the path width of the overflow channel 5 can be designed to be narrower than the path width of the microchannel 3 to slow down the flow rate into the overflow channel 5. This allows the bacterial solution to be fully mixed with the pre-placed reagent 41 before flowing into the overflow channel 6, preventing a large amount of bacterial solution from flowing in the same direction. This ensures that the sample can be fully mixed with the pre-placed reagent 41, and makes it more difficult for the bacterial solution flowing into the overflow channel 6 to flow back into the microchannel 3, effectively avoiding the problem of cross-infection.

[0073] The sample then reacts with the pre-placed reagent 41 in each reaction tank 4. The gas generated during the reaction is discharged from the test carrier 1 through the vent 7, preventing excessive gas pressure in the sealed disc from damaging the test carrier 1 and causing it to overflow into other microchannels 3, thus indirectly preventing contamination of the bacterial solution. Through these steps, the AST experiment can be easily completed. Subsequently, the effectiveness of the antibiotic can be determined by observing the color of the indicator on the test carrier 1.

[0074] Please refer to the following at the same time. Figure 7 The figure shown is an exploded view of the second preferred embodiment of the present invention. As can be clearly seen from the figure, this embodiment is very similar to the above embodiment, except that the test carrier 1 has at least one fixing part 13 for fixing to a test device 8, and the test carrier 1 has a foolproof part 14 for confirming the setting position of the test carrier 1. The fixing part 13 is used to prevent the test carrier 1 from detaching from the test device 8 when it rotates, and the foolproof part 14 is used to confirm the setting position of the test carrier 1 to avoid the test sample overflowing due to reversal. In this embodiment, the fixing part 13 is exemplified by the limiting track on the side wall of the positioning part 111, such as an L-shaped track. The testing device 8 has a block-shaped fixing member 82 that is connected to the fixing part 13 on the shaft 81. This effectively prevents the test carrier 1 from falling off. The foolproof part 14 is exemplified by the annular groove at the bottom of the test carrier 1. Therefore, the testing device 8 has a foolproof indicator 83 with an annular rib shape corresponding to the foolproof part 14. If the user accidentally sets the test carrier 1 in the wrong direction, the foolproof part 14 will be facing upwards, preventing the foolproof indicator 83 from being inserted into the test carrier 1, thus making the test carrier 1 unable to be fixed, thereby warning the user to set it in the wrong direction.

[0075] Please refer to the following at the same time. Figure 8 The figure shown is an exploded view of the third preferred embodiment of the present invention. As can be clearly seen from the figure, this embodiment is very similar to the above embodiments, except that the rotation method of the test carrier 1 and the corresponding arrangement of the error prevention part 14 and the fixing part 13 are changed. In this embodiment, the bottom of the test carrier 1 does not have a positioning part used as a shaft, and the test device 8 does not have a shaft pivotally connected to the test carrier 1. Instead, the test device 8 uses a ring-shaped fixing member 82 that can be driven to rotate from the outer edge by an electric roller for limiting the test carrier 1. This allows the test carrier 1 to be placed inside the fixing member 82 while being driven to rotate by the fixing part 13, thus preventing it from detaching during rotation. As for the foolproof part 14, it is exemplified by a notch formed on the side of the lower plate 11. The lower edge of the inner sidewall of the fixing member 82 protrudes inward to form a protruding foolproof indicator 83. Since the upper plate 12 does not have the foolproof part 14, when the user accidentally places the test carrier 1 in the wrong direction, it will hit the foolproof indicator 83 and cannot be inserted, thus achieving the purpose of foolproofing.

[0076] Please refer to the following at the same time. Figure 9 The figure shown is a perspective sectional view of the fourth preferred embodiment of the present invention. As can be clearly seen from the figure, this embodiment is largely similar to the previous embodiments, except that a flow-limiting groove 23 is provided on the side of the central injection section 2 connecting to the microchannels 3. The flow-limiting groove 23 is a flat, annular slit with a height less than the height of the microchannels 3. Specifically, it is a drainage outlet formed by a recess from the bottom edge of the wall of the central injection section 2 into the wall surface. In this way, regardless of the instantaneous amount of sample flowing into the microchannels 3, it will... Because the flow-limiting groove 23 is designed to limit the amount of sample entering the microchannel 3, and because the flow-limiting groove 23 is a ring connecting the entrances of each microchannel 3, when a large amount of sample rushes towards the entrance of a certain microchannel 3, the flow-limiting groove 23 can not only block it immediately, but also guide the excess sample to both sides, so that the sample in the central injection section 2 is first concentrated in the flow-limiting groove 23, and then slowly flows into each microchannel 3, so that the sample in each reaction tank 4 is distributed more evenly, and the amount of sample remaining in the central injection section 2 can be reduced.

[0077] Please refer to the following at the same time. Figure 10 and Figure 11 The figures show a perspective view and a cross-sectional view from another angle of the fifth preferred embodiment of the present invention. As can be clearly seen from the figures, this embodiment is largely similar to the previous embodiments, except that the cross-sectional area of ​​each microchannel 3 is 100μm to 300μm square. This results in the microchannel 3 forming shallow grooves on the surface of the test carrier 1. When used with the testing device, the test carrier 1 is inverted, with the microchannel 3 and the sealing film (upper disc 12) both at the bottom, and the injection port 22 of the central injection part 2 located at the bottom of the test carrier 1, exposed at the top when inverted. Furthermore, the number of supporting and limiting parts 112 is increased to four. This significantly reduces the volume of the microchannel 3. In this embodiment, the cross-sectional area of ​​the microchannel 3 is 200 x 200μm. 2 For example, this further enhances the effects of slowing the flow rate of bacterial solution into overflow channel 5, mixing bacterial solution with pre-placed reagent 41, suppressing the forward flow of large amounts of bacterial solution, preventing bacterial solution in overflow channel 6 from flowing back into microchannel 3, and avoiding cross-infection. As for the situation where the bottom of reaction tank 4 and overflow channel 6 are connected due to the inverted operation, because of the aforementioned centrifugal force and the design of overflow channel 5 being located on the side of microchannel 3 opposite to the rotation direction of test carrier 1, the problem of bacterial solution flooding into overflow channel 6 is basically eliminated.

[0078] Please refer to the following at the same time. Figure 12The figure shown is a plan view of the sixth preferred embodiment of the present invention. As can be clearly seen from the figure, this embodiment is very similar to the above embodiments, except that each reaction tank 4 has a converging groove 42 on the side connecting to each overflow channel 5. The converging groove 42 is slightly convex, so that the reaction tank 4 forms a teardrop shape when combined with it. The tapered part 51 is connected to one side of the converging groove 4. In this way, when the amount of bacterial liquid in the reaction tank 4 is greater than its volume, it will be preferentially concentrated at the converging groove 42 to guide the excess sample to the overflow channel 6 in real time. A balance is achieved between limiting the unintended flow of the sample into the overflow channel 6 and preventing the large amount of sample from flowing into the overflow channel 6. With the design of the converging groove 42, it can quickly guide the excess sample into the overflow channel 6. Under normal circumstances, it can also work with the tapered part 51 to prevent the sample from accidentally entering the overflow channel 6. Furthermore, the gathering effect of the converging groove 42 can push the bubble-like gas from the rear of the overflow channel 6 towards the exhaust port 7, thereby improving the exhaust effect.

[0079] The above description is only a preferred embodiment of the present utility model and does not limit the patent scope of the present utility model. Therefore, any simple modifications and equivalent structural changes made based on the contents of the present utility model specification and drawings should also be included in the patent scope of the present utility model.

Claims

1. A reagent disc structure for drug sensitivity testing, characterized in that, The test carrier includes: a test carrier; at least two support limiting portions formed in the test carrier for supporting the test carrier; a central injection portion disposed between the support limiting portions for adding a sample and limiting the insertion depth of an injection tool through the support limiting portions; a plurality of micro flow channels radially and spaced apart from the central injection portion and each connected to the central injection portion, so that the sample is uniformly flowed into each micro flow channel by centrifugal force when the test carrier is rotated; a plurality of reaction grooves respectively disposed in each micro flow channel, and each reaction groove has a volume of 20-80 μl; a plurality of pre-disposed reagents respectively disposed in each reaction groove, and each pre-disposed reagent is a reagent specially used for drug sensitivity test; a plurality of overflow channels respectively formed on a side of each reaction groove away from the micro flow channel and connected to the micro flow channel; a plurality of overflow grooves respectively formed on a side of each overflow channel and connected to the overflow channel; a plurality of tapered portions formed on each overflow channel, and the opening connected to the side of each reaction groove is larger than the opening connected to the side of each overflow groove; and a plurality of exhaust holes respectively disposed on a side of each overflow groove and connected to the overflow groove.

2. The drug sensitivity test kit structure according to claim 1, wherein the drug sensitivity test kit structure is a kit for testing the sensitivity of a drug against a cancer. The test carrier has at least one fixing portion for fixing with a test device, and has a fool-proof portion for confirming the setting direction of the test carrier.

3. The reagent disc structure for drug sensitivity testing as described in claim 1, characterized in that, Each reaction groove has a converging groove on the side connected to the overflow channel.

4. The drug sensitivity test kit structure according to claim 1, wherein the drug sensitivity test kit structure is a kit for testing the sensitivity of a drug against a cancer. The cross-sectional area of each micro flow channel is 100-300 μm square.

5. The drug sensitivity test reagent disc structure according to claim 1, wherein the drug sensitivity test reagent disc structure is a disc structure having a diameter of 8 mm or less. The outer edge of the central injection portion has a flow limiting groove connected to the side of the micro flow channels. The cross-sectional area of each micro flow channel is 100-300 μm square. The outer edge of the central injection portion has a flow limiting groove connected to the side of the micro flow channels.

Images